Clinical trial reportJournal for immunotherapy of cancerPublished
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
Regional connection
Verified An author affiliation on the Europe PMC record names Thomas Jefferson University. Affiliation source
- Institution
- Thomas Jefferson University
- County
- Philadelphia County
Publication record
- Type
- Clinical trial report
- Venue
- Journal for immunotherapy of cancer
- Published
- Topic
- Clinical care
- Subject terms
- Lymphocytes, Tumor-Infiltrating; Humans; Melanoma; Skin Neoplasms; Immunotherapy, Adoptive; Immune Checkpoint Inhibitors; Immunotherapy; Immunotherapy, adoptive; Lymphocytes, Tumor-infiltrating; Clinical Trials, Phase Ii As Topic
- PubMed ID
- 36600653
- PubMed Central ID
- PMC9748991
- Open access
- Yes, open
- Added to directory
- Source checked